Symbols

CARL

Carlsmed·NASDAQ

--(--)

CARL fundamentals

CARL Q4 2025 Earnings

Carlsmed (CARL) released its earnings on Feb 25, 2026: revenue was 15.16M (YoY --), beat estimates; EPS was -0.32 (YoY --), beat estimates.

Revenue / YoY

15.16M

EPS / YoY

-0.32

Report date

Feb 25, 2026

CARL Earnings Call Summary for Q4,2025

Revenue Surge: 86% YoY growth to $50.5 million in 2025, driven by lumbar and cervical procedure expansion.
Innovative Launches: Bilateral aprevo and corra cervical plates set for H2 2026, with early surgeon adoption of cervical procedures.
Operational Excellence: 6-day production lead time enables faster surgeon response and procedure planning.
Cervical Momentum: NTAP reimbursement and personalized plating drive 10% of existing users adopting cervical, targeting $70-75 million 2026 revenue.
Financial Health: $109.9 million cash balance; 2026 guidance reflects 44% growth and path to cash flow breakeven.

Earnings

EPS

Revenue

Revenue & Expenses

CARL has released its 2025 Q4 earnings report, with revenue of 15.16M, reflecting a YoY change of 61.19%, and net profit of -8.61M, showing a YoY change of -82.48%. The Sankey diagram below clearly presents CARL's revenue sources and cost distribution.

Key Indicators

Carlsmed (CARL) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Carlsmed (CARL)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Carlsmed (CARL)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Carlsmed (CARL)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown